Marina DiStefano

Marina DiStefano

Auto-generated profile, based on publicly available information

Marina DiStefano

The Broad Institute of MIT and Harvard, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NSNatasha T. Strande
Natasha T. Strande
ERErin Rooney Riggs
Erin Rooney Riggs
ABAdam H. Buchanan
Adam H. Buchanan
OCOzge Ceyhan-Birsoy
Ozge Ceyhan-Birsoy
MDMarina DiStefano
Marina DiStefano
JBJonathan S. Berg
Jonathan S. Berg

4 May 2022 in Genetics in Medicine
Verified
Journal Article
Open access
MDMarina T. DiStefano
Marina T. DiStefano
SGScott Goehringer
Scott Goehringer
LBLawrence Babb
Lawrence Babb
FAFowzan S. Alkuraya
Fowzan S. Alkuraya
JAJoanna Amberger
Joanna Amberger
HHeidi Rehm
Heidi Rehm
Several groups and resources provide information that pertains to the validity of gene-disease relationships used in genomic medicine and research; however, universal standards and terminologies to define the evidence base for the role of a gene in disease, and a single harmonized resource were lacking. To tackle this issue, the Gene Curation Coalition (GenCC) was formed. The GenCC drafted harmonized definitions for differing levels of gene-disease validity based on existing resources, and performed a modified Delphi survey with three rounds to narrow the list of terms. The GenCC also developed a unified database to display curated gene-disease validity assertions from its members. Based on 241 survey responses from the genetics community, a consensus term set was chosen for grading gene-disease validity and database submissions. As of December 2021, the database contains 15,241 gene-disease assertions on 4,569 unique genes from 12 submitters. When comparing submissions to the database from distinct sources, conflicts in assertions of gene-disease validity ranged from 5.3% to 13.4%. Terminology standardization, sharing of gene-disease validity classifications, and resolution of curation conflicts will facilitate collaborations across international curation efforts and in turn, improve consistency in genetic testing and variant interpretation.

11 October 2018 in Human Mutation
Verified
Journal Article
Open access
PDF file
MIMichael A. Iacocca
Michael A. Iacocca
JCJoana Rita Chora
Joana Rita Chora
ACAlain Carrié
Alain Carrié
TFTomáš Freiberger
Tomáš Freiberger
SLSarah E. Leigh
Sarah E. Leigh
OPon behalf of the ClinGen FH Variant Curation Expert Panel
on behalf of the ClinGen FH Variant Curation Expert Panel
Accurate and consistent variant classification is imperative for incorporation of rapidly developing sequencing technologies into genomic medicine for improved patient care. An essential requirement for achieving standardized and reliable variant interpretation is data sharing, facilitated by a centralized open‐source database. Familial hypercholesterolemia (FH) is an exemplar of the utility of such a resource: it has a high incidence, a favorable prognosis with early intervention and treatment, and cascade screening can be offered to families if a causative variant is identified. ClinVar, an NCBI‐funded resource, has become the primary repository for clinically relevant variants in Mendelian disease, including FH. Here, we present the concerted efforts made by the Clinical Genome Resource, through the FH Variant Curation Expert Panel and global FH community, to increase submission of FH‐associated variants into ClinVar. Variant‐level data was categorized by submitter, variant characteristics, classification method, and available supporting data. To further reform interpretation of FH‐associated variants, areas for improvement in variant submissions were identified; these include a need for more detailed submissions and submission of supporting variant‐level data, both retrospectively and prospectively. Collaborating to provide thorough, reliable evidence‐based variant interpretation will ultimately improve the care of FH patients.

1 November 2019 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
JSJun Shen
Jun Shen
AOAndrea M. Oza
Andrea M. Oza
Ignacio del CastilloIgnacio del Castillo
Ignacio del Castillo
HDHatice Duzkale
Hatice Duzkale
TMTatsuo Matsunaga
Tatsuo Matsunaga
LSLisa Schimmenti
Lisa Schimmenti

20 December 2024 in Genome Medicine
Verified
Journal Article
Open access
PDF file
RHReece Hart
Reece Hart
IFIvo F. A. C. Fokkema
Ivo F. A. C. Fokkema
MDMarina DiStefano
Marina DiStefano
RHRos Hastings
Ros Hastings
JLJeroen F. J. Laros
Jeroen F. J. Laros
JDJohan T. Den Dunnen
Johan T. Den Dunnen
Background: The Human Genome Variation Society (HGVS) Nomenclature is the global standard for describing and communicating variants in DNA, RNA, and protein sequences in clinical and research genomics. This manuscript details recent updates to the HGVS Nomenclature, highlighting improvements in governance, community engagement, website functionality, and underlying implementation of the standard. Methods: The HGVS Variant Nomenclature Committee (HVNC) now operates under the Human Genome Organization (HUGO), facilitating broader community feedback and collaboration with related standards organizations. The website has been redesigned using modern documentation tools and practices. The specification was updated to include guidance for transcript selection and to align with recent cross-consortia recommendations for the representation of gene fusions. A formal computational grammar was introduced to improve the precision and consistency of variant descriptions. Results: Major improvements in HGVS Nomenclature v. 21.1 include a redesigned website with enhanced navigation, search functionality, and mobile responsiveness; a new versioning policy aligned with software management practices; formal mechanisms for community feedback and change proposals; and adoption of Extended Backus-Naur Form (EBNF) for defining syntax. The specification now recommends MANE Select transcripts where appropriate and includes updated guidance for representing adjoined transcripts and gene fusions. All content is freely available under permissive licenses at hgvs-nomenclature.org. Conclusions: These advancements establish a more sustainable foundation for maintaining and evolving the HGVS Nomenclature while improving its accessibility and utility. The introduction of formal computational grammar marks a crucial step toward unambiguous variant descriptions that can be reliably processed by both humans and machines. Combined with enhanced community engagement mechanisms and improved guidance, these changes position the HGVS Nomenclature to better serve the evolving needs of clinical and research genomics while maintaining the stability that users require.

11 May 2022 in Cell Genomics
Verified
Journal Article
Open access
CTCourtney Thaxton
Courtney Thaxton
JGJennifer Goldstein
Jennifer Goldstein
MDMarina DiStefano
Marina DiStefano
KWKathleen Wallace
Kathleen Wallace
PWP. Dane Witmer
P. Dane Witmer
JBJonathan S. Berg
Jonathan S. Berg
The dilemma of how to categorize and classify diseases has been debated for centuries. The field of medical genetics has historically approached nosology based on clinical phenotypes observed in patients and families. Advances in genomic sequencing and understanding of genetic contributions to disease often provoke a need to reassess these classifications. The Clinical Genome Resource (ClinGen) has developed frameworks to classify the strength of evidence underlying monogenic gene-disease relationships, variant pathogenicity, and clinical actionability. It is therefore necessary to define the disease entity being evaluated, which can be challenging for genes associated with multiple conditions and/or a broad phenotypic spectrum. We therefore developed criteria to guide “lumping and splitting” decisions and improve consistency in defining monogenic gene-disease relationships. Here, we outline the precuration process, the lumping and splitting guidelines with examples, and describe the implications for clinical diagnosis, informatics, and care management.